Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacology of Anti-Cancer Drugs

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1554632

Pan-cancer analysis identified CD248 as a potential target for multiple tumor types

Provisionally accepted
Li Guo Li Guo Yan Liao Yan Liao Xuyang Zhang Xuyang Zhang Rongjuan Guo Rongjuan Guo Zheng Wang Zheng Wang Deqin Yang Deqin Yang *
  • Stomatological Hospital of Chongqing Medical University, Chongqing, China

The final, formatted version of the article will be published soon.

    Objective: Tumors remain a major cause of death worldwide due to late-stage presentation and late diagnosis. Cell therapies have revolutionized the landscape in the precision treatment of tumors. However, there are still many challenges that limit the therapeutic efficacy. Additionally, cancer treatment also entails a major financial burden throughout the entire phase, making it preferable to find a specific biomarker for the early prognosis of the tumor. Methods: In this study, the role of CD248 in pan-cancer was analyzed through diverse tumor-associated databases, such as the Human Protein Atlas Database, the GEPIA2 Database, the cBioPortal Database, the TIMER Database, the STRING tool, and so on. In addition, CD248 mRNA and protein levels were assessed in a series of head and neck squamous cell carcinoma (HNSC) cell lines using qRT-PCR and western blot. Furthermore, siCD248 was used to detect the effect of CD248 on the invasion, migration, and proliferation of HNSC cells by transwell assay, scratch wound healing assay, and EdU assay, respectively. Results: CD248 expression was significantly increased and correlated with advanced stage and poor prognosis in various tumors. Genetic alterations of CD248 were also associated with a poor prognosis of patients. Single-cell sequencing revealed that CD248 was mainly expressed on fibroblasts within the stroma, and its expression was positively correlated with the infiltration of immune cells in tumors. In addition, CD248 interacted with 11 common tumor biomarkers. Experiment results indicated that CD248 mRNA and protein expression were upregulated in HNSC cell lines, and inhibition of CD248 suppresses the invasion, migration, and proliferation of HNSC cells. Conclusion: High CD248 expression played a crucial role in pan-cancer, including immune cell infiltration, tumor progression and metastasis, and patient prognosis. CD248 plays a crucial role in tumor cells' functions, including invasion, migration, and proliferation. All these findings indicated that CD248 may be a novel oncoprotein and a potential therapeutic target for pan-cancer.

    Keywords: CD248, Pan-cancer, immune cell, overall survival, single-cell sequencing, targeted therapy

    Received: 02 Jan 2025; Accepted: 28 Mar 2025.

    Copyright: © 2025 Guo, Liao, Zhang, Guo, Wang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Deqin Yang, Stomatological Hospital of Chongqing Medical University, Chongqing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more